deferoxamine has been researched along with Acute Disease in 52 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)." | 9.15 | Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. ( Goldstein, JN; Gomes, J; Greenberg, S; Morgenstern, LB; Palesch, Y; Schlaug, G; Selim, M; Torbey, M; Waldman, B; Xi, G; Yeatts, S, 2011) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 7.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "In the present study, the effects of deferoxamine on tissue lactate and malondialdehyde (MDA) levels after cerebral ischemia in rabbits was studied." | 7.72 | Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia. ( Ak, A; Bariskaner, H; Dogan, N; Gurbilek, M; Ustun, ME; Yosunkaya, A, 2003) |
| "We studied the effect of iron chelators, 2,2'-dipyridyl and desferrioxamine, on cerulein-induced pancreatitis in rats." | 7.71 | Amelioration of cerulein-induced acute pancreatitis by 2,2'-dipyridyl in rats. ( Kitano, Y; Makino, I; Matsumoto, K; Tanaka, H; Yokoyama, K, 2002) |
| "Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)." | 5.15 | Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. ( Goldstein, JN; Gomes, J; Greenberg, S; Morgenstern, LB; Palesch, Y; Schlaug, G; Selim, M; Torbey, M; Waldman, B; Xi, G; Yeatts, S, 2011) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 3.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "In the present study, the effects of deferoxamine on tissue lactate and malondialdehyde (MDA) levels after cerebral ischemia in rabbits was studied." | 3.72 | Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia. ( Ak, A; Bariskaner, H; Dogan, N; Gurbilek, M; Ustun, ME; Yosunkaya, A, 2003) |
| "To determine the effects of combination of deferoxamine and meropenem in acute necrotizing pancreatitis." | 3.72 | Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. ( Ateskan, U; Babaoglu, E; Comert, B; Deveci, S; Doruk, H; Kocar, IH; Mas, MR; Mas, NN; Ozkomur, ME; Tasci, I; Yasar, M, 2003) |
| "We studied the effect of iron chelators, 2,2'-dipyridyl and desferrioxamine, on cerulein-induced pancreatitis in rats." | 3.71 | Amelioration of cerulein-induced acute pancreatitis by 2,2'-dipyridyl in rats. ( Kitano, Y; Makino, I; Matsumoto, K; Tanaka, H; Yokoyama, K, 2002) |
| " Further, there is lack of agreement about the benefits of deferoxamine (Dfx) in the treatment of anemia and oxidative stress during inflammation and chronic diseases." | 3.69 | Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine. ( Mitjavila, MT; Muntané, J; Puig-Parellada, P, 1995) |
| "Deferoxamine treatment attenuated TBI-induced hydrocephalus and heme oxygenase-1 upregulation." | 1.40 | Deferoxamine attenuates acute hydrocephalus after traumatic brain injury in rats. ( Chen, Z; Hua, Y; Keep, RF; Xi, G; Zhao, J, 2014) |
| "Liver fibrosis was additionally suppressed in the bile-duct ligation model by ID." | 1.35 | Attenuation of acute and chronic liver injury in rats by iron-deficient diet. ( Ikeda, K; Kawada, N; Nakajima, Y; Nakatani, K; Ogawa, T; Otogawa, K; Shiga, R, 2008) |
| " Three doses of 200, 300 and 400 mg/kg DFO were used either alone or in combination with pyrimethamine." | 1.30 | Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice. ( Mahmoud, MS, 1999) |
| "The drug of choice for the treatment of iron poisoning is desferrioxamine, though the best route of administration, dose, and duration of treatment are unclear." | 1.28 | Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. ( Adamson, IY; Bowden, DH; Kowalski, S; Sienko, A; Tenenbein, M, 1992) |
| "Treatment with deferoxamine in vivo failed to influence these in vitro measures of neutrophil oxidative metabolism." | 1.28 | Effect of deferoxamine pretreatment on acute pneumonic pasteurellosis and neutrophil oxidative metabolism in calves. ( Killingsworth, CR; Slocombe, RF; Watson, GL, 1990) |
| "Acute myelofibrosis (AMF) was diagnosed in a 59-yr-old black male in September 1978, on the basis of pancytopenia, lack of hepatosplenomegaly, fibrosis of the marrow, and paucity of teardrop red blood cells in the peripheral blood." | 1.26 | Karyotypic polymorphism in acute myelofibrosis. ( Koppitch, F; Mahmood, S; Mayeda, K; Nemitz, B; Shah, I, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (42.31) | 18.7374 |
| 1990's | 14 (26.92) | 18.2507 |
| 2000's | 9 (17.31) | 29.6817 |
| 2010's | 6 (11.54) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Van der Loo, LE | 1 |
| Aquarius, R | 1 |
| Teernstra, O | 1 |
| Klijn, K | 1 |
| Menovsky, T | 1 |
| van Dijk, JMC | 1 |
| Bartels, R | 1 |
| Boogaarts, HD | 1 |
| Zhao, J | 1 |
| Chen, Z | 2 |
| Xi, G | 3 |
| Keep, RF | 1 |
| Hua, Y | 2 |
| Egashira, Y | 1 |
| Chaudhary, N | 1 |
| Pandey, AS | 1 |
| Selim, M | 1 |
| Yeatts, S | 1 |
| Goldstein, JN | 1 |
| Gomes, J | 1 |
| Greenberg, S | 1 |
| Morgenstern, LB | 1 |
| Schlaug, G | 1 |
| Torbey, M | 1 |
| Waldman, B | 1 |
| Palesch, Y | 1 |
| Song, S | 1 |
| Christova, T | 1 |
| Perusini, S | 1 |
| Alizadeh, S | 1 |
| Bao, RY | 1 |
| Miller, BW | 1 |
| Hurren, R | 1 |
| Jitkova, Y | 1 |
| Gronda, M | 1 |
| Isaac, M | 1 |
| Joseph, B | 1 |
| Subramaniam, R | 1 |
| Aman, A | 1 |
| Chau, A | 1 |
| Hogge, DE | 1 |
| Weir, SJ | 1 |
| Kasper, J | 1 |
| Schimmer, AD | 1 |
| Al-awar, R | 1 |
| Wrana, JL | 1 |
| Attisano, L | 1 |
| Vlahakos, D | 1 |
| Arkadopoulos, N | 1 |
| Kostopanagiotou, G | 1 |
| Siasiakou, S | 1 |
| Kaklamanis, L | 1 |
| Degiannis, D | 1 |
| Demonakou, M | 1 |
| Smyrniotis, V | 1 |
| Sankar, J | 1 |
| Shukla, A | 1 |
| Khurana, R | 1 |
| Dubey, N | 1 |
| Mahmoud, MS | 1 |
| Bariskaner, H | 1 |
| Ustun, ME | 1 |
| Ak, A | 1 |
| Yosunkaya, A | 1 |
| Dogan, N | 1 |
| Gurbilek, M | 1 |
| Ateskan, U | 1 |
| Mas, MR | 1 |
| Yasar, M | 1 |
| Deveci, S | 1 |
| Babaoglu, E | 1 |
| Comert, B | 1 |
| Mas, NN | 1 |
| Doruk, H | 1 |
| Tasci, I | 1 |
| Ozkomur, ME | 1 |
| Kocar, IH | 1 |
| Jiang, Y | 1 |
| Xue, ZH | 1 |
| Shen, WZ | 1 |
| Du, KM | 1 |
| Yan, H | 1 |
| Yu, Y | 1 |
| Peng, ZG | 1 |
| Song, MG | 1 |
| Tong, JH | 1 |
| Huang, Y | 1 |
| Lübbert, M | 1 |
| Chen, GQ | 1 |
| Otogawa, K | 1 |
| Ogawa, T | 1 |
| Shiga, R | 1 |
| Nakatani, K | 1 |
| Ikeda, K | 1 |
| Nakajima, Y | 1 |
| Kawada, N | 1 |
| Goulding, R | 1 |
| Henretig, FM | 1 |
| Temple, AR | 1 |
| Blake, DR | 1 |
| Hall, ND | 1 |
| Bacon, PA | 1 |
| Dieppe, PA | 1 |
| Halliwell, B | 1 |
| Gutteridge, JM | 1 |
| Ward, PA | 1 |
| Till, GO | 1 |
| Kunkel, R | 1 |
| Beauchamp, C | 1 |
| Shah, I | 1 |
| Mayeda, K | 1 |
| Koppitch, F | 1 |
| Mahmood, S | 1 |
| Nemitz, B | 1 |
| Crapo, JD | 1 |
| LaLonde, C | 1 |
| Ikegami, K | 1 |
| Demling, R | 1 |
| Muntané, J | 1 |
| Puig-Parellada, P | 1 |
| Mitjavila, MT | 1 |
| Mills, KC | 1 |
| Curry, SC | 1 |
| Cohen, CS | 1 |
| Leardi, A | 1 |
| Caraglia, M | 1 |
| Selleri, C | 1 |
| Pepe, S | 1 |
| Pizzi, C | 1 |
| Notaro, R | 1 |
| Fabbrocini, A | 1 |
| De Lorenzo, S | 1 |
| Musicò, M | 1 |
| Abbruzzese, A | 1 |
| Bianco, AR | 1 |
| Tagliaferri, P | 1 |
| al-Rimawi, HS | 1 |
| al-Sheyyab, M | 1 |
| Batieha, A | 1 |
| el-Shanti, H | 1 |
| Abuekteish, F | 1 |
| Soybir, G | 1 |
| Köksoy, F | 1 |
| Ekiz, F | 1 |
| Yalçin, O | 1 |
| Fincan, K | 1 |
| Haklar, G | 1 |
| Yüksel, M | 1 |
| Roberts, WL | 1 |
| Smith, PT | 1 |
| Martin, WJ | 1 |
| Rainey, PM | 1 |
| Nakamura, H | 1 |
| Rose, PG | 1 |
| Blumer, JL | 1 |
| Reed, MD | 1 |
| Ren, X | 1 |
| Dorrington, KL | 1 |
| Maxwell, PH | 1 |
| Robbins, PA | 1 |
| Chekanov, VS | 1 |
| Nikolaychik, V | 1 |
| Bergeron, RJ | 1 |
| Wiegand, J | 1 |
| Brittenham, GM | 1 |
| Kitano, Y | 1 |
| Yokoyama, K | 1 |
| Matsumoto, K | 1 |
| Makino, I | 1 |
| Tanaka, H | 1 |
| Strom, RL | 1 |
| Schiller, P | 1 |
| Seeds, AE | 1 |
| Bensel, RT | 1 |
| Gratadour, P | 1 |
| Fouque, D | 1 |
| Chevalier, P | 1 |
| Vial, T | 1 |
| Chossegros, P | 1 |
| Laville, M | 1 |
| Labeeuw, M | 1 |
| Zech, P | 1 |
| Tenenbein, M | 1 |
| Kowalski, S | 1 |
| Sienko, A | 1 |
| Bowden, DH | 1 |
| Adamson, IY | 1 |
| Niederau, C | 1 |
| Niederau, M | 1 |
| Borchard, F | 1 |
| Ude, K | 1 |
| Lüthen, R | 1 |
| Strohmeyer, G | 1 |
| Ferrell, LD | 1 |
| Grendell, JH | 1 |
| Slocombe, RF | 1 |
| Watson, GL | 1 |
| Killingsworth, CR | 1 |
| Mahoney, JR | 1 |
| Hallaway, PE | 1 |
| Hedlund, BE | 1 |
| Eaton, JW | 1 |
| Guerin, A | 1 |
| London, G | 1 |
| Marchais, S | 1 |
| Metivier, F | 1 |
| Pelisse, JM | 1 |
| Finkelstein, I | 1 |
| Toledo-Pereyra, LH | 1 |
| Castillo, M | 1 |
| Castellanos, J | 1 |
| Cases, A | 2 |
| Campistol, JM | 2 |
| Sabater, M | 1 |
| López-Pedret, J | 1 |
| Revert, L | 2 |
| Kelly, J | 1 |
| Sabater, J | 1 |
| Torras, A | 1 |
| Montoliu, J | 1 |
| López, I | 1 |
| Mofenson, HC | 2 |
| Caraccio, TR | 1 |
| Sharieff, N | 1 |
| Kramer, TT | 1 |
| Saucke, L | 1 |
| Griffith, RW | 1 |
| Kunesh, JP | 1 |
| Snyder, R | 1 |
| Greensher, J | 1 |
| Barker, GA | 1 |
| Brown, TC | 1 |
| Hosking, CS | 2 |
| Cartei, G | 1 |
| Barry, M | 1 |
| Burg, G | 2 |
| Robertson, WO | 1 |
| Barr, DG | 1 |
| Fraser, DK | 1 |
| Fainshtein, FE | 1 |
| Trubina, NS | 1 |
| Sobaleva, IuG | 1 |
| Rozanova, NS | 1 |
| Voronina, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2a Exploratory Clinical Trial to Evaluate the Safety of Oral Deferiprone (14 Days) Including Its Effect on Decreasing the Content of Iron in Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) sIRB[NCT03754725] | Phase 1/Phase 2 | 66 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage[NCT02216513] | Early Phase 1 | 2 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.) | ||
| Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial[NCT02875262] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2022-12-02 | Recruiting | ||
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
| Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225] | Phase 2 | 294 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy[NCT00990587] | Phase 1 | 20 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | ||
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 3 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 1 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 9 |
| Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 12 |
| Normal Saline | 14 |
Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 0 |
Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 1 |
| Normal Saline | 2 |
Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 4 |
Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 9 |
| Normal Saline | 5 |
Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 39 |
| Normal Saline | 49 |
Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 24 |
| Normal Saline | 26 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 61 |
| Normal Saline | 48 |
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 48 |
| Normal Saline | 47 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 97 |
| Normal Saline | 92 |
"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 91 |
| Normal Saline | 82 |
Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| All cause | Cause by acute respiratory distress syndrome | |
| Deferoxamine Mesylate | 20 | 2 |
| Normal Saline | 23 | 1 |
Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Onset to treatment time <=12 hours | Onset to treatment time >12 hours | |
| Deferoxamine Mesylate | 15 | 33 |
| Normal Saline | 19 | 28 |
3 reviews available for deferoxamine and Acute Disease
| Article | Year |
|---|---|
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Iron chelators for acute stroke.
Topics: Acute Disease; Bias; Deferoxamine; Hemorrhagic Stroke; Humans; Iron Chelating Agents; Neuroprotectiv | 2020 |
Acute iron poisoning.
Topics: Acute Disease; Chelation Therapy; Deferoxamine; Humans; Iron; Poisoning | 1994 |
Treatment of acute iron poisoning.
Topics: Acidosis; Acute Disease; Bicarbonates; Deferoxamine; Diarrhea; Edetic Acid; Emetics; Humans; Infusio | 1971 |
4 trials available for deferoxamine and Acute Disease
| Article | Year |
|---|---|
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F | 2011 |
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; | 2011 |
Effect of desferrioxamine in acute haemolytic anaemia of glucose-6-phosphate dehydrogenase deficiency.
Topics: Acute Disease; Adolescent; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Glucose | 1999 |
Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.
Topics: Acute Disease; Adolescent; Adult; Carbon Dioxide; Carotid Body; Deferoxamine; Erythropoietin; Female | 2000 |
45 other studies available for deferoxamine and Acute Disease
| Article | Year |
|---|---|
Deferoxamine attenuates acute hydrocephalus after traumatic brain injury in rats.
Topics: Acute Disease; Animals; Brain; Brain Injuries; Deferoxamine; Hydrocephalus; Iron; Lateral Ventricles | 2014 |
Acute Brain Injury after Subarachnoid Hemorrhage.
Topics: Acute Disease; Acute-Phase Proteins; Animals; Brain Injuries; Brain Ischemia; Deferoxamine; Hemoglob | 2015 |
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi | 2012 |
Near fatal iron intoxication managed conservatively.
Topics: Acute Disease; Deferoxamine; Dehydration; Drug Overdose; Emergency Service, Hospital; Female; Fluid | 2013 |
Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Topics: Acute Disease; Animals; Antiprotozoal Agents; Deferoxamine; Disease Models, Animal; Drug Therapy, Co | 1999 |
Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia.
Topics: Acute Disease; Animals; Brain; Brain Ischemia; Deferoxamine; Electroencephalography; Iron Chelating | 2003 |
Deferoxamine and meropenem combination therapy in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Bacteria; Bacterial Infections; Catheterization; Deferoxamine; Drug Therapy, | 2003 |
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha.
Topics: Acute Disease; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line, Tumor; Core Bi | 2005 |
Attenuation of acute and chronic liver injury in rats by iron-deficient diet.
Topics: Acute Disease; Animals; Apoptosis; Chemokine CCL2; Chronic Disease; Deferoxamine; Hepatocytes; Inter | 2008 |
The treatment of acute poisoning.
Topics: Acute Disease; Antidotes; Atropine; Barbiturates; Carbon Monoxide Poisoning; Chlorpromazine; Deferox | 1967 |
Acute iron poisoning in children.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Central Nervous System Diseases; Child; Child, Pres | 1984 |
Effect of a specific iron chelating agent on animal models of inflammation.
Topics: Acute Disease; Animals; Brain; Catalysis; Chronic Disease; Deferoxamine; Disease Models, Animal; Fem | 1983 |
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury.
Topics: Acute Disease; Animals; Capillaries; Complement Activation; Complement C3; Complement System Protein | 1983 |
Karyotypic polymorphism in acute myelofibrosis.
Topics: Acute Disease; Blood Transfusion; Bone Marrow Cells; Chromosomes, Human, 1-3; Chromosomes, Human, 4- | 1982 |
"Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation".
Topics: Acute Disease; Administration, Inhalation; Aerosols; Animals; Antioxidants; Deferoxamine; Disease Mo | 1994 |
Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Animals; Bronchoalveolar Lavage Fluid; Carboxyh | 1994 |
Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine.
Topics: Acute Disease; Anemia, Iron-Deficiency; Animals; Carrageenan; Chronic Disease; Deferoxamine; Disease | 1995 |
Studies in acute iron poisoning. I. Desferrioxamine In the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations, by Charles F. Whitten et al, Pediatrics, 1965;36:322-335; and Studies in acute iron
Topics: Acute Disease; Antidotes; Deferoxamine; History, 20th Century; Humans; Iron; Poisoning | 1998 |
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
Topics: Acute Disease; Antidotes; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cytarabine; Def | 1998 |
The effects of free oxygen radical scavenger and platelet-activating factor antagonist agents in experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Deferoxamine; Disease Models, Animal; Edema; Free Radi | 1999 |
Performance characteristics of three serum iron and total iron-binding capacity methods in acute iron overdose.
Topics: Acute Disease; Chelating Agents; Deferoxamine; Drug Overdose; Evaluation Studies as Topic; Humans; I | 1999 |
Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis.
Topics: Acute Disease; Aged; Aged, 80 and over; Alum Compounds; Deferoxamine; Delirium; Female; Humans; Inje | 2000 |
Iron contributes to endothelial dysfunction in acute ischemic syndromes.
Topics: Acute Disease; Coronary Circulation; Coronary Disease; Deferoxamine; Endothelial Growth Factors; End | 2002 |
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Topics: Acute Disease; Animals; Blood Pressure; Cebus; Chronic Disease; Deferoxamine; Disease Models, Animal | 2002 |
Amelioration of cerulein-induced acute pancreatitis by 2,2'-dipyridyl in rats.
Topics: 2,2'-Dipyridyl; Acute Disease; Animals; Ceruletide; Deferoxamine; Edema; Injections, Intraperitoneal | 2002 |
Fatal iron poisoning in a pregnant female.
Topics: Acute Disease; Adolescent; Deferoxamine; Female; Gastrointestinal Hemorrhage; Humans; Iron; Liver; P | 1976 |
[Acute hepatitis induced by deferoxamine in a patient under chronic hemodialysis].
Topics: Acute Disease; Aged; Chemical and Drug Induced Liver Injury; Deferoxamine; Hemodialysis, Home; Human | 1992 |
Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.
Topics: Acute Disease; Adult; Deferoxamine; Female; Humans; Infusions, Intravenous; Iron; Lung; Male; Poison | 1992 |
Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis.
Topics: Acute Disease; Administration, Oral; Allopurinol; Animals; Antioxidants; Catalase; Ceruletide; Choli | 1992 |
Effect of deferoxamine pretreatment on acute pneumonic pasteurellosis and neutrophil oxidative metabolism in calves.
Topics: Acute Disease; Animals; Cattle; Cattle Diseases; Deferoxamine; Iron; Kidney; Neutrophils; Oxidation- | 1990 |
Acute iron poisoning. Rescue with macromolecular chelators.
Topics: Acute Disease; Animals; Deferoxamine; Disease Models, Animal; Iron; Iron Chelating Agents; Male; Mic | 1989 |
Acute deafness and desferrioxamine.
Topics: Acute Disease; Adult; Deafness; Deferoxamine; Female; Humans | 1985 |
Comparative analysis of pharmacological agents following small bowel ischemia.
Topics: Acute Disease; Allopurinol; Animals; Deferoxamine; Drug Combinations; Free Radicals; Intestinal Dise | 1988 |
Desferrioxamine-induced acute neurosensorial deafness.
Topics: Acute Disease; Adult; Deafness; Deferoxamine; Female; Humans; Kidney Failure, Chronic | 1988 |
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
Topics: Acute Disease; Adult; Aged; Deferoxamine; Female; Hearing Loss; Hearing Loss, Bilateral; Hearing Los | 1988 |
Iron sepsis: Yersinia enterocolitica septicemia possibly caused by an overdose of iron.
Topics: Acute Disease; Deferoxamine; Diseases in Twins; Female; Humans; Infant; Iron; Male; Sepsis; Yersinia | 1987 |
Desferoxamine and iron dextran in acute Salmonella cholerae-suis infection in pigs.
Topics: Acute Disease; Animals; Body Temperature; Deferoxamine; Drug Therapy, Combination; Erythrocyte Count | 1986 |
Acute iron poisoning in infancy. Guide to treatment.
Topics: Acute Disease; Deferoxamine; Humans; Infant; Infusions, Parenteral; Ipecac; Iron; Male | 1974 |
Acute iron poisoning-clinical features and management.
Topics: Acute Disease; Australia; Child, Preschool; Deferoxamine; Female; Gastric Lavage; Humans; Infant; In | 1974 |
[A case of acute poisoning caused by ferrous fumarate. (Anatomo-clinical, physiopathological and therapeutic findings)].
Topics: Acute Disease; Adult; Deferoxamine; Digestive System; Edetic Acid; Female; Fumarates; Gastric Lavage | 1969 |
[Therapy of porphyrias].
Topics: Acute Disease; Adenine Nucleotides; Antimalarials; Bicarbonates; Bloodletting; Deferoxamine; Diet Th | 1971 |
[Therapy of porphyrias].
Topics: Acute Disease; Bone Marrow Diseases; Chlorpromazine; Deferoxamine; Erythropoiesis; Humans; Phospholi | 1972 |
Acute iron poisoning in children: role of chelating agents.
Topics: Acute Disease; Child; Child, Preschool; Deferoxamine; Female; Gluconates; Humans; Infant; Iron; Male | 1968 |
[Use of desferal and some data on hemosiderosis in hypo- and aplastic anemias].
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Chronic Disease; Deferoxamine; Female; Hemochrom | 1968 |
Radiology in the management of acute iron poisoning.
Topics: Acute Disease; Deferoxamine; Diagnosis, Differential; Gastric Lavage; Humans; Infant; Iron; Lung; Ma | 1969 |